All In Biotech

Drug Trial Radar · NCT04720313

NXC-201 (Formerly HBI0101) Multiple Myeloma

A Phase 1 Dose Escalation and Safety Study of NXC-201 (Formerly HBI0101) CART in BCMA-Expressing Multiple Myeloma Patients

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 1, 2021

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nexcella Inc.
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients

Conditions

  • Dose Escalation and Safety

Interventions

  • NXC-201 (formerly HBI0101)Drug

    NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of MTDTime frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah University Hospital

    Jerusalem, Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.